Literature DB >> 1826450

Elevated energy expenditure in cancer patients with solid tumours.

A Hyltander1, C Drott, U Körner, R Sandström, K Lundholm.   

Abstract

Cancer patients (n = 106) and non-cancer subjects (n = 96) were classified as weight stable (n = 70) or weight-losing (n = 132). Cancer patients had elevated resting energy expenditure (REE) compared with either weight-losing (23.6 [0.4] vs. 20.5 [0.5] kcal/kg per day, P less than 0.001) or weight-stable controls (22.0 [0.6] vs. 17.9 [0.4], P less than 0.001). Cancer patients had increased fat oxidation irrespective of weight loss (1.24 [0.07] vs. 0.87 [0.04] mg/kg per min; 1.07 [0.04] vs. 0.78 [0.04], P less than 0.001). Elevated energy expenditure was counter-regulated by a decrease in thyroid hormones. Abnormal liver function had no impact on REE in either group. Heart rate was the most powerful factor for prediction of high energy expenditure in both patients and controls. Elevated energy expenditure was related to the increased heart rate in cancer patients in a significantly higher proportion than that in controls. Increased metabolic rate is a significant component behind weight loss in cancer disease, independent of malnutrition and an elevated adrenergic state may be a likely explanation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1826450     DOI: 10.1016/0277-5379(91)90050-n

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  29 in total

1.  Immunohistochemical and quantitative mRNA assessment of ghrelin expression in gastric and oesophageal adenocarcinoma.

Authors:  Marcus Mottershead; Emmanuel Karteris; Jill Y Barclay; Saira Suortamo; Mark Newbold; Harpal Randeva; Chuka U Nwokolo
Journal:  J Clin Pathol       Date:  2006-06-02       Impact factor: 3.411

2.  Alpha1-and beta2-adrenoceptors in the human liver with mass-forming intrahepatic cholangiocarcinoma: density and coupling to adenylate cyclase and phospholipase C.

Authors:  W T Kassahun; B Günl; A Tannapfel; F R Ungemach; J Hauss; G Abraham
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-11-15       Impact factor: 3.000

Review 3.  Cancer cachexia: understanding the molecular basis.

Authors:  Josep M Argilés; Sílvia Busquets; Britta Stemmler; Francisco J López-Soriano
Journal:  Nat Rev Cancer       Date:  2014-10-09       Impact factor: 60.716

Review 4.  Defining the molecular nexus of cancer, type 2 diabetes and cardiovascular disease.

Authors:  S M Cabarcas; E M Hurt; W L Farrar
Journal:  Curr Mol Med       Date:  2010-11       Impact factor: 2.222

Review 5.  New drugs for the anorexia-cachexia syndrome.

Authors:  Mellar P Davis
Journal:  Curr Oncol Rep       Date:  2002-05       Impact factor: 5.075

6.  Pharmacological interference with tissue hypercatabolism in tumour-bearing rats.

Authors:  L Tessitore; P Costelli; F M Baccino
Journal:  Biochem J       Date:  1994-04-01       Impact factor: 3.857

7.  Lymphosarcoma-induced alterations in hepatic adrenergic receptors: implications to the hypoglycemia of cancer cachexia.

Authors:  Susan J Hemmings; Thomas R Wilson
Journal:  Mol Cell Biochem       Date:  2003-08       Impact factor: 3.396

Review 8.  Nutritional support in multimodal therapy for cancer cachexia.

Authors:  Ingvar Bosaeus
Journal:  Support Care Cancer       Date:  2008-01-15       Impact factor: 3.603

9.  Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer.

Authors:  J S Falconer; K C Fearon; C E Plester; J A Ross; D C Carter
Journal:  Ann Surg       Date:  1994-04       Impact factor: 12.969

10.  Weight gain, metabolic syndrome, and breast cancer recurrence: are dietary recommendations supported by the data?

Authors:  Colin E Champ; Jeff S Volek; Joshua Siglin; Lianjin Jin; Nicole L Simone
Journal:  Int J Breast Cancer       Date:  2012-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.